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Abstract
The Dementias Platform UK Data Portal is a data repository facilitating access to data for 3 370 929 individuals in 42 cohorts. 
The Data Portal is an end-to-end data management solution providing a secure, fully auditable, remote access environment 
for the analysis of cohort data. All projects utilising the data are by default collaborations with the cohort research teams 
generating the data. The Data Portal uses UK Secure eResearch Platform infrastructure to provide three core utilities: data 
discovery, access, and analysis. These are delivered using a 7 layered architecture comprising: data ingestion, data curation, 
platform interoperability, data discovery, access brokerage, data analysis and knowledge preservation. Automated, stream-
lined, and standardised procedures reduce the administrative burden for all stakeholders, particularly for requests involving 
multiple independent datasets, where a single request may be forwarded to multiple data controllers. Researchers are pro-
vided with their own secure ‘lab’ using VMware which is accessed using two factor authentication. Over the last 2 years, 
160 project proposals involving 579 individual cohort data access requests were received. These were received from 268 
applicants spanning 72 institutions (56 academic, 13 commercial, 3 government) in 16 countries with 84 requests involving 
multiple cohorts. Projects are varied including multi-modal, machine learning, and Mendelian randomisation analyses. Data 
access is usually free at point of use although a small number of cohorts require a data access fee.
Keywords Cohorts · Epidemiology · Data platform · Data repository · Data access · Data management
Introduction
Here we describe the Dementias Platform UK (DPUK) 
Data Portal (https ://porta l.demen tiasp latfo rm.uk/) [1]. 
The Data Portal is a collaboration between DPUK and 
a growing number of cohort research teams who wish to 
make their data globally accessible. DPUK was established 
by the Medical Research Council (MRC) to accelerate the 
development of new treatments for dementia. The Data 
Portal is a component infrastructure of DPUK, designed to 
exploit the opportunities provided by cohort data to inform 
experimental medicine and to improve access to cohort 
data more widely. It is a data repository facilitating access 
to data for 3 370 929 individuals in 42 cohorts. The Data 
Portal provides a secure, fully auditable, remote access 
environment for the analysis of cohort data. The Data 
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Portal supports the FAIR principles (Findability, Acces-
sibility, Interoperability and Reusability) to improve the 
infrastructure supporting the re-use of data [2].
Arguments for multi-cohort-focused data reposito-
ries include: (1) as research questions focus on smaller 
effect sizes, access is required to data at-scale to achieve 
statistical purchase, (2) as emerging research questions 
become more complex, access to diverse multi-modal data 
is needed for rigorous hypothesis testing, (3) as scientific 
rigour increases there is growing recognition of the value 
of triangulation and replication using independent data-
sets, (4) as cohort datasets increase in size the transfer 
of large datasets is decreasingly feasible, (5) as cohort 
datasets become more complex the mastering of bespoke 
data models for survey, omics (genomics, proteomics and 
metabolomics), imaging and device data becomes bur-
densome, (6) as cohort datasets become more sensitive 
the non-auditable use of data is decreasingly acceptable. 
Whilst these issues can be addressed individually, the Data 
Portal provides an integrated solution.
The Data Portal is an end-to-end data management 
solution designed to support cohort data sharing. All pro-
jects utilising the data are by default collaborations with 
the cohort research teams generating the data. Although 
it has the three core utilities of data discovery, access, and 
analysis, to achieve these it operates across seven layers 
(Fig. 1).
Layer 1: Data ingestion
The data journey begins with upload to the Data Portal. 
Datasets and data dictionaries are received from cohorts on 
an ‘as-is’ basis along with other supporting documentation. 
The Data Portal operates within the UK Secure eResearch 
Platform (UKSeRP) environment according to ISO 27001 
[3] and operates exclusively as a data processor according to 
the UK Data Protection Act 2018 [4] and EU General Data 
Protection Regulation 2016 [5]. DPUK facilitates the legal 
engagements necessary for data transfer into the Data Portal 
on behalf of data controllers, by ensuring robust contractual 
arrangements are in place as an overarching mechanism for 
data governance and use [6]. In practice the data controller 
is considered to be the principal investigator for the dataset. 
A dataset is removed from the Data Portal upon receipt of a 
wet-ink signature request from the data controller.
Layer 2: Data curation
Upon receipt, ‘native’ data are curated to a common data 
model (C-Surv). The C-Surv ontology is designed to sim-
plify the analytic challenge of working across multiple data-
sets and multiple modalities by providing standard struc-
ture, variable naming and value labelling conventions. Other 
data models, CDISC [7], OMOP [8], or HPO [9] involve 
structural complexity that is rarely relevant to cohort-based 
Fig. 1  Data Portal architecture
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analyses. An example variable name using the C-Surv model 
is given below:
The cohort is identified using a three digit alphabetic charac-
ter (GEN for Generation Scotland), and category-level data 
by a two digit numeric character (05 for physical health sta-
tus). The measure is described by an alphanumeric acronym 
(PAINCHESTEVR for: Do you ever get pain or discomfort 
in your chest?). This is followed by an integer giving the 
number of repeat measurements within a study wave (_0 
indicates there were no repeat measurements). Finally, an 
integer suffix indicates study wave (_1 for recruitment, _2 
for the first follow-up, etc.). This data model is a contribu-
tion to a wider debate on how global access to cohort data 
can be achieved.
C-Surv is optimised for the analysis of ‘flat-file’ data. 
Higher order data must be pre-processed prior to curation. 
The XNAT [10] imaging platform is used to receive and 
process DICOM and NIfTI files. For genetics, variant call 
format and allele frequency data may be uploaded. C-Surv 
is also designed to improve the efficiency of data selection 
and management from the applicants and administrators’ 
perspectives. There are 22 categories and 132 sub-catego-
ries, which may be used for data selection as an alternative 
to individual variable selection. The ontology is machine-
readable for mapping to other ontologies. Researchers may 
request access to either native or curated data. Standardisa-
tion does not imply harmonisation i.e. comparability (equiv-
alence) of values and/or distributions across variables. Data 
harmonisation is implicitly purpose specific. DPUK under-
takes a very limited harmonisation programme solely to sup-
port data discovery (see Layer 4). Data curation is resource 
intensive and is ongoing. To accelerate the process we are 
developing machine-learning approaches, which currently 
achieve an 80% accuracy.
Layer 3: Interoperability
We anticipate a global mixed-model data access environ-
ment that respects sovereign boundaries and requires the 
highest levels of security. In practice, this involves the 
integration of individual participant data across datasets 
(‘pooled’ analyses) and the integration of summary data 
across datasets (‘federated’ analyses). Both models require 
interoperability between data platforms across national 
boundaries. DPUK supports the development of interop-
erability in several ways. In partnership with UKSeRP, 
we provide access to our software solutions to other data 
platforms to facilitate architectural compatibility. We also 
engage with other data platforms to develop interoper-
ability across architectures. In collaboration with Gates 
GEN05_PAINCHESTEVR_0_1
Ventures and other data platforms, we are working to 
develop a high-level data-gateway for cross-platform data 
access.
Layer 4: Data discovery
A tiered data discovery pathway begins with the Cohort 
Matrix [11] which provides a high-level comparison of 
data availability for each cohort. The Cohort Directory [12] 
enables detailed exploration across cohorts using a range 
of metadata categories. The Cohort Explorer [13] provides 
access to a set of 30 variables harmonised across cohorts 
to enable feasibility analysis. Adding cohorts to the Cohort 
Explorer is ongoing. As the Cohort Explorer provides access 
to harmonised data, login to the Data Portal is required. Data 
discovery is a dynamic area and the development of increas-
ingly ergonomic and intuitive tools is anticipated. This is 
likely to include the identification of high priority variable 
sets and variable selection algorithms through the analysis 
of user-activity and the development of application program-
ming interfaces (APIs) to rapidly reproduce data selection 
(see Layer 7). DPUK welcomes user feedback and collabo-
ration to inform an ongoing programme of discovery tool 
development.
Layer 5: Data access brokerage
Automated third-party brokerage, allowing submission of 
a single data access request to multiple data controllers, 
reduces the researcher administrative burden. Standard 
cross-cohort access agreements and streamlined decision-
making procedures simplifies the application and approvals 
process for all stakeholders. Access requests can be speci-
fied at the level of detail required by the data controller and 
if approval is granted, a standard access agreement must 
be completed by both parties prior to access being granted. 
The application form is a synthesis of key issues that are 
addressed by most, if not all, the individual cohort access 
management procedures, fail-fast criteria have been devel-
oped to facilitate rapid and transparent decision-making by 
data controllers. These comprise the proposal not being in 
the public interest, potential identifiability of participants, 
no clear scientific rationale, no appropriate analysis plan, 
or a conflict of scientific interest. Upon access approval 
by a cohort data access committee (DAC), completion by 
the applicant of a data access agreement is required prior 
to access being granted. Upon receipt of a completed data 
access agreement, data access is granted within several days 
for any one cohort [14]. Data access is normally free at the 
point of use with a small number of cohorts levying a data 
access fee (Table 1).
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Table 1  Collaborating cohorts
1 Data access process: Portal- DPUK procedure sufficient; Cohort- Cohort specific procedure required; Por-
tal + Cohort- DPUK procedure may be used for the initial application, followed by cohort-specific proce-
dure
2 Variable selection: Portal- DPUK procedure sufficient; Cohort- Cohort specific procedure required
$ Data access fee payable
¥ Data uploaded directly to the applicants servers
Data avail-
ability
Cohort N Data access  process1 Variable  selection2
Full or partial upload complete or in process
1 Airwave [15] 53,280 Portal Portal
2 AMPLE [16] 80 Portal Portal
3 BRACE [17] 2389 Portal Portal
4 CamPaIGN [18] 142 Portal Portal
5 CaPS [19] 2512 Portal Portal
6 CFAS I [20] 18,005 Portal Portal
7 CFAS II [21] 7524 Portal Portal
8 DELPHIC [22] 2000 Portal Portal
9 DFP pilot [23] 21 Portal Portal
10 ELSA [24] 11,391 Portal Portal
11 EPINEF [25] 2008 Portal Portal
12 EXTEND [26] 10,000 Portal Portal
13 Generation Scotland [27] 23,960 Portal Portal
14 GERAD EOAD [28] 4397 Portal Portal
15 GERAD LOAD [28] 10,454 Portal Portal
16 ICICLE-PD [29] 318 Portal Portal
17 Memento [30] 2323 Portal Portal
18 NIMROD [31] 276 Portal Cohort
29 OPDC Discovery [32] 1589 Portal Portal
20 PICNICS [33] 282 Portal Portal
21 SAIL-DeC [34] 1,246,557 Portal Portal
22 SMC Amyloid [35] 120 Portal Portal
23 TRACK-HD [36] 366 Portal Portal
24 Whitehall II [37]$ 10,308 Portal + Cohort Cohort
Upload per project
25 ALSPAC Children [38]$¥ 15,630 Portal + Cohort Cohort
26 ALSPAC Parents [39]$¥ 22,761 Portal + Cohort Cohort
27 BDR [40] 2963 Portal + Cohort Cohort
28 Cam-CAN [41] 2683 Portal + Cohort Cohort
29 CHARIOT [42] 24,509 Portal + Cohort Cohort
30 DIAN [43] 437 Portal Cohort
31 EPIC Norfolk [44] 25,639 Portal + Cohort Cohort
32 HealthWise Wales [45] 6100 Portal + Cohort Cohort
33 LBC1936 [46] ¥ 1091 Portal + Cohort Cohort
34 Million Women [47] 1,319,475 Portal + Cohort Cohort
35 NICOLA [48] 8504 Portal Cohort
36 NSHD [49] 5362 Portal + Cohort Cohort
37 PREVENT [50] 700 Portal Cohort
38 PRIME [51] 2745 Portal Cohort
39 PROTECT [52] 14,000 Portal + Cohort Cohort
40 SABRE [53] 4858 Portal + Cohort Cohort
41 UK Biobank [54]$¥ 502,655 Cohort Cohort
42 UK GENFI [55] 515 Portal Cohort
Total 3,370,929
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Layer 6: Data analysis
The analysis environment is VMware based with each 
researcher allocated their own private personal ‘lab’ (desk-
top) into which approved data are moved, and from which 
they can access a range of pre-loaded generic and specialist 
software packages. Bespoke software may also be uploaded 
upon approval. VMware clients are available for a range of 
operating system including Windows, Linux, IOS, Mac, 
and Android. A standard desktop is provided for research-
ers seeking to access standard phenotypic data on the Por-
tal. The standard desktop has the following specification: 
Windows 7/10, 8 GB RAM, and 4 CPUs. It is pre-loaded 
with R, RStudio, SPSS, SAS, Stata, Python, Eclipse, MAT-
LAB, SQL Server Management Studio, Microsoft Office. 
Statistical software, such as R and Python, can connect to 
its official library/package/index directory to enable con-
figuration of software on a per-user basis. Larger desktops 
are available on request (32 GB RAM with 8 CPUs, 128 GB 
RAM and 16 CPUs) which are more suitable for large-scale 
multi-modal analyses such as omics and imaging analyses, 
and for machine learning.
Storage is scalable according to the study requirements, 
with basic access to data stored on our systems free to all 
users. Studies needing unusually large amounts of storage 
to ingress their own at-scale data will be subject to potential 
charges which will be discussed with researchers as part of 
the desktop set-up. High Performance Computing and non-
Windows operating systems are available upon request. The 
Data Portal also offers consortia-based workspace; providing 
an independent and transparent storage, access and analysis 
solution for use by multiple institutions.
Two-factor authentication is required to access approved 
datasets. This involves the provision of a username with 
password creation, and an authentication code generated 
by an app on a mobile device of the applicant’s choosing. 
Data may not be removed from the Data Portal. However, 
tables, graphs and scripts for export are submitted to the data 
export panel for approval. Manuscripts may be prepared in 
the Data Portal so that collaborators who are registered users 
may contribute without the need for manuscript download. 
A facility for import is also available, enabling researchers 
to upload scripts and additional datasets from outside the 
Data Portal to reside within their approved DPUK datasets.
Layer 7: Knowledge environment
Cohort data grow in quantity and can be complex, but 
ultimately there is the need for the transition from data to 
knowledge and insight. In response to this challenge, the 
Data Portal is developing a Knowledge Hub to organise and 
make information readily accessible on the key activities of 
the Data Portal. The immediate purpose of the Knowledge 
Hub is to enable collaborative knowledge building; enabling 
researchers to understand what is available, what is known, 
and where there are knowledge gaps. It also serves as a 
knowledge preservation repository enabling the storage of 
linked datasets and analysis code with persistent identifiers 
for rapid access and replication. DPUK welcomes collabora-
tion in the development of this hub.
Application for access can be made through the Data Por-
tal: https ://porta l.demen tiasp latfo rm.uk/ [56].
Results
Data resources
DPUK collaborates with 42 clinical and population cohorts 
(Table 1). Of these, 24 (n = 1 410 302) have either completed 
or are in the process of uploading full or partial datasets 
and 18 (n = 1 960 627) upload data on a per-project basis. 
The data are diverse. Clinical cohort studies include familial 
disease cohorts [43, 55], disease focused patient cohorts [32, 
36], ageing focused population cohorts [21, 24, 40, 57], re-
purposed cardiovascular cohorts [19, 37], birth cohorts [38, 
49], repurposed cancer cohorts [15, 44], and disease agnos-
tic cohorts [45, 47, 54]. In terms of real world evidence, the 
Data Portal provides access to an e-cohort (SAIL-DeC) cov-
ering health records for 1.2 m individuals including 130 k 
dementia cases [34]. Data availability varies according to 
cohort but includes epidemiologic survey, imaging, genetics, 
and linked administrative data. The Data Portal provides a 
link to the UK-CRIS Network for natural language process-
ing of 2.5 m UK mental health records [58]. Overall, these 
cohorts and the data modalities represented, provide an unu-
sually rich and complex data environment.
Data resource use
From launch in November 2017 to end of January 2019, 
160 project proposals involving 579 individual cohort data 
access requests were received. These were received from 
268 applicants spanning 72 institutions (56 academic, 13 
commercial, 3 government) in 16 countries with 84 requests 
involving multiple cohorts.
Of the 160 project proposals, 40 failed triage due to 
under-specification and were not forwarded to cohort DACs. 
The 120 projects that were forwarded to DACs involved 396 
individual cohort access requests, 19 of which were with-
drawn by the applicant pre-approval. Of the 377 access 
requests considered 171 (45%) were approved, 80 (21%) 
were declined, 78 (21%) were closed following non-response 
after 200 days from either the applicant or the cohort, 19 
(5%) ceased after approval and 29 (8%) are in process. Of 
the 80 declined requests, 49 (61%) were due to the data 
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requested either not existing or not being relevant for the 
analysis.
The data requests were diverse. Projects include Men-
delian randomisation, imaging, psychometric, and machine 
learning studies, alongside risk stratification studies and 
dementia prediction and diagnosis modelling. Other studies 
are less dementia specific including trajectories of longitu-
dinal assessment of comorbidities between mental health, 
hormonal indicators and cognitive change; the impact of 
child adversity on adult outcomes; the longitudinal tracking 
and determinants of well-being and cognitive performance; 
and successful cognitive ageing in 90 + year olds.
To facilitate innovative and exploratory analyses, the 
Data Portal can be configured as a ‘sandbox’ environment, 
without compromising data security or cohort governance 
principles. An example of this was the hosting of a three-day 
multidisciplinary workshop (datathon) for 40 data scientists 
at the Alan Turing Institute utilising the Deep and Frequent 
Phenotyping pilot study data [23]. These multi-modal data 
include Magneto-encephalography (MEG), Positron Emis-
sion Tomography (PET), structural and functional MRI, 
ophthalmology, gait, and serial cognitive and clinical assess-
ment. The Data Portal was used to host 25 data scientists in a 
datathon at the University of Exeter and Swansea University, 
during which traditional regression and machine learning 
procedures were used to interrogate the data within the vir-
tual desktop interface. A datathon at the University of East 
Anglia hosted 60 attendees, mostly early career researchers, 
using data from the Deep and Frequent Phenotyping Study 
[23], the English Longitudinal Study of Ageing [24], and 
the Caerphilly Prospective Study [59]. The datathon pro-
gramme is ongoing with a further 6 planned for 2019. The 
sandbox environment is also suitable for teaching and train-
ing purposes as it enables access to standardised datasets by 
multiple users within a secure environment.
Data Portal performance
Data Portal utility varies according to the extent that stand-
ardised procedures are used. Currently, 38 cohorts (90%) 
accept our standard legal agreements, 28 cohorts (67%) 
accept our streamlined data access process, with a further 
13 accepting a DPUK application as an initial enquiry. For 
variable selection, 22 (52%) cohorts accept the use of our 
variable selection tools with the remainder requiring the use 
of cohort-specific variable selection tools (Table 1).
Triage is rapid, usually upon receipt. Cohort DAC deci-
sion times vary according to the complexity of the project, 
clarity of the proposal, and the DAC meeting frequency. 
DPUK policy is to consider a project closed (in effect 
expired) if there has been no response from the cohort 
DAC within 200 days. Our target DAC response time is 
28 days. Current performance has a median value of 28 days 
(mean = 40). Time from approval to data access is depend-
ent on the completion of the data access agreement by the 
applicant. Where data are already uploaded to the Data Por-
tal access is typically given with 24 h of receiving the com-
pleted Data Access Agreement. Where data are uploaded on 
a per-project basis, access is dependent on the cohort data 
management process. Typically, upload of native data (not 
curated by DPUK) occurs within 2 weeks and can be made 
accessible to the researcher immediately.
Discussion
Rapid data access continues to be a challenge for research-
ers, funders, and governments. The DPUK Data Portal is one 
of several initiatives to address this issue. In the dementia 
space, other data platforms are available. The JPND Global 
Cohort Directory [60] provides contact details for 175 
cohorts (n = 3 586 109) whilst the IALSA Network [61] pro-
vides details for 110 cohorts (n = 1 485 410). More sophis-
ticated and convenient data discovery tools are provided by 
GAAIN [62] with 47 cohorts (n = 480 020). GAAIN also 
offers centralised processing for selected datasets. EMIF-AD 
[61] offers a comprehensive data harmonisation programme 
for a selection of their 60 catalogued cohorts (n = 135 959) 
and 18 electronic health records datasets (n = 65 m). For 
selected datasets EMIF-AD provides centralised cohort data 
processing facilities through the TranSMART platform [63].
Data Portal benefits
However, in providing independent trusted third-party data 
management, the data repository approach has several ben-
efits. Although the Data Portal is optimised for dementia, its 
remote access model provides a generic solution that can be 
adapted to any outcome for which relevant data are available. 
Specifically, by automating, streamlining and standardising 
procedures, decision-making can be more precise, quicker, 
and more transparent, and the practice of repeated data trans-
fers avoided.
For cohort research teams a repository substantially 
reduces the administrative burden of routine data manage-
ment tasks, particularly avoiding repeated data transfers. 
This assists cohorts in meeting their data sharing obliga-
tions, and releases cohort-based data scientists to focus on 
increasing the scientific value of their data.
For researchers a repository provides a single point of 
contact and a single standard procedure for accessing mul-
tiple independent datasets. Within the Data Portal this sup-
ports data discovery, feasibility modelling, access manage-
ment and analysis. The use of a common data model reduces 
data preparation times and reduces uncertainty due to unnec-
essary variation in data pre-processing.
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For the research community as a whole, a repository facil-
itates knowledge management including the linking of code-
to-dataset through the use of persistent identifiers (Digital 
Object Identifiers: DOIs), the development and discover-
ability of APIs for rapid replication, and the improvement 
of the end-to-end user experience through adaptive learning.
Repositories have an important role in the democratisa-
tion of science. The Data Portal allows remote and secure 
data analysis, enabling the best ideas to be tested in high 
quality data from any location with suitable connectivity. 
This is fundamentally empowering to researchers without 
access to high-end computing, particularly in developing 
countries.
Data Portal challenges
New infrastructure requires new working practice, which 
brings challenges to platform operators, data controllers and 
data users.
Operational challenges for platform operators focus on 
improving the user experience and increasing the scientific 
opportunity. Data platforms are complex infrastructures 
that integrate the highest levels of security and governance 
requirements for accessing large, complex, and non-standard 
datasets. They are also integrated within larger computing 
facilities which require specific resource allocation for com-
puter intensive operations.
In this context, improving the user experience is an incre-
mental process. For example, improving data discovery and 
visualisation tools to improve the precision of data access 
requests, streamlining decision making to reducing approval 
times, and developing links to similar resources globally. 
All involve engagement with different stakeholders, each of 
which have different expectations and requirements.
For some data controllers the repository ‘trusted third-
party’ approach to data management involves uncertainty. 
Whilst the practice of managing access through repeated data 
transfer may be labour intensive, it is familiar. Uncertainty 
surrounds the legal status of Electronic Health Records 
(EHRs) data accessed via the platform, quality of the pro-
posed science, the relevance (and existence) of the requested 
data, and potential conflicts of scientific interest. The legal 
status of accessing EHR data linked to research data using 
third party platforms is a grey area in the UK. Although 
there is no change in data controller, and no forward shar-
ing to a third-party data controller, current UK data sharing 
licenses have not anticipated the Data Portal solution. Dis-
cussions are underway in the UK data community to resolve 
this issue. Wider access also brings reduced control, and 
data controllers can be concerned over the reputation of their 
datasets if used for egregious science. In response DPUK 
strongly advises a collaboration with cohort research groups 
as this is the quickest way to understand a dataset and receive 
expert advice on how to approach its analysis. To facilitate 
good science it is not unreasonable for cohort research teams 
to insist on a collaborative approach. That 61% of declined 
access requests (see section: Data Resource Use) were due 
to the data requested either not existing or not being relevant 
for the analysis is to an extent a matter of due diligence on 
the part of the applicant, but it can also be a matter of judge-
ment. The impact of conflict of interest depends largely on 
the perspective of the DAC. In an age of increasingly large 
and complex analyses, many cohorts are underpowered for 
emerging research questions. Cohort research team interests 
can be well-served though transparent collaborative relation-
ships. To reassure data controllers, their approval is required 
for all data access, all use is auditable, data cannot be down-
loaded, and data are erased upon request.
For researchers, accessing data via a repository may be 
less convenient than through their host institution. However, 
the additional security measures are not onerous and are bal-
anced by improved data access. A secure repository requires 
an account and user authentication. Whilst these procedures 
may be simple (two-factor authentication takes ≈ 10 s), they 
require a level of familiarity before becoming second nature. 
For access approval, epidemiologic, imaging, and genetic 
communities each have different conventions over what 
constitutes an appropriate data request. By streamlining 
and standardising the application process DPUK encour-
ages coalescence around the development of common stand-
ards that are widely accepted. The informatics infrastructure 
required by these groups also varies in terms of operating 
systems, compute power, and software. Our response is to 
provide flexibility. Standard environments are available that 
suit the requirements of most users, but bespoke environ-
ments are built on request including access to high perfor-
mance computing.
In the pursuit of scientific rigour, increased data access is 
only part of the equation. Also required is a commensurate 
development in analytic competence. That 40 project pro-
posals failed a not very demanding triage process, suggests 
that some analysts are unaware of the value and complexity 
of the data resources that are available. Although DPUK 
can increase the opportunity for training via the Data Portal, 
there is a wider responsibility to up-skill analysts to take 
advantage of this.
Looking ahead
The mission of the Data Portal is to increase the realised 
scientific value of cohort data. Future developments include 
developing linkage to electronic health records. In partner-
ship with Health Data Research UK, DPUK is developing a 
centralised system enabling DPUK cohorts to link research 
data to routinely collected data. In partnership with Gates Ven-
tures, DPUK along with other platforms is developing global 
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connectivity. DPUK is also working with academic and indus-
try partners to provide digital phenotyping using devices such 
as smart phones, for collaborating cohorts. A third develop-
ment is the use of cohort data to risk-stratify for trials recruit-
ment. For dementia, there is a growing need for risk stratifica-
tion by phenotype according to genotype in order to recruit 
to highly targeted experimental medicine studies. Cohorts, 
by virtue of lead-in data are well positioned to support these 
studies. DPUK collaborates with the Airwave and HealthWise 
Wales cohorts to provide genotyping and cognitive testing for 
experimental medicine recruitment. DPUK welcomes extend-
ing this collaboration to other cohorts.
Conclusions
The DPUK Data Portal was established by the MRC to sup-
port the development of new treatments for dementia by using 
cohort data to inform experimental medicine. It is recognition 
of the unique value of cohort data and a contribution to the 
wider debate on how best to support cohort studies and facili-
tate their contribution to the wider research environment. By 
streamlining procedures for cohort research teams, increasing 
data accessibility for researchers, reducing costs, and adding 
value, the Data Portal is an investment in the future of cohort 
studies.
Applications for access can be made through the Data Por-
tal: https ://porta l.demen tiasp latfo rm.uk/.
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